Publications by authors named "Sandra Kanan"

Claim this Profile
I
Ibrutinib Monotherapy in Relapsed or Refractory, Transformed Diffuse Large B-cell Lymphoma.
Solomon A Graf, Ryan D Cassaday, Karolyn Morris, Jenna M Voutsinas, Qian Vicky Wu, Sandra Kanan

Clin Lymphoma Myeloma Leuk· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modified VR-CAP, Alternating With Rituximab and High-dose Cytarabine: An Effective Pre-transplant Induction Regimen for Mantle Cell Lymphoma.
Stephen D Smith, Shruti Gandhy, Ajay K Gopal, Prathima Reddy, Mazyar Shadman, Sandra Kanan

Clin Lymphoma Myeloma Leuk· January 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pegylated GCSF Can Be Used With First-Line da-EPOCH-R Without Compromising Dose Intensity, Safety, or Efficacy.
Prathima Reddy, Sandra Kanan, Andrew Cowan, Houston Warren, Brian Till

Clin Lymphoma Myeloma Leuk· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Rituximab intolerance in patients with Waldenström macroglobulinaemia.
Jorge J Castillo, Sandra Kanan, Kirsten Meid, Robert Manning, Zachary R Hunter

Br J Haematol· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clonal architecture of CXCR4 WHIM-like mutations in Waldenström Macroglobulinaemia.
Lian Xu, Zachary R Hunter, Nicholas Tsakmaklis, Yang Cao, Guang Yang, Sandra Kanan

Br J Haematol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Survival outcomes of secondary cancers in patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Jorge J Castillo, Adam J Olszewski, Sandra Kanan, Kirsten Meid, Zachary R Hunter

Am J Hematol· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Yang Cao, Guang Yang, Zachary R Hunter, Xia Liu, Lian Xu, Sandra Kanan

Br J Haematol· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Incidence of secondary malignancies among patients with Waldenström macroglobulinemia: An analysis of the SEER database.
Jorge J Castillo, Adam J Olszewski, Zachary R Hunter, Sandra Kanan, Kirsten Meid

Cancer· July 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall survival and competing risks of death in patients with Waldenström macroglobulinaemia: an analysis of the Surveillance, Epidemiology and End Results database.
Jorge J Castillo, Adam J Olszewski, Sandra Kanan, Kirsten Meid, Zachary R Hunter

Br J Haematol· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Ibrutinib in previously treated Waldenström's macroglobulinemia.
Steven P Treon, Christina K Tripsas, Kirsten Meid, Diane Warren, Gaurav Varma, Sandra Kanan

N Engl J Med· April 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CXCR4 WHIM-like frameshift and nonsense mutations promote ibrutinib resistance but do not supplant MYD88(L265P) -directed survival signalling in Waldenström macroglobulinaemia cells.
Yang Cao, Zachary R Hunter, Xia Liu, Lian Xu, Guang Yang, Sandra Kanan

Br J Haematol· March 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Carfilzomib, rituximab, and dexamethasone (CaRD) treatment offers a neuropathy-sparing approach for treating Waldenström's macroglobulinemia.
Steven P Treon, Christina K Tripsas, Kirsten Meid, Sandra Kanan, Patricia Sheehy

Blood· July 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mesothelin variant 1 is released from tumor cells as a diagnostic marker.
Ingegerd Hellstrom, John Raycraft, Sandra Kanan, Niranjan Y Sardesai, Thorsten Verch

Cancer Epidemiol Biomarkers Prev· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Melanoma cells transfected to express CD83 induce antitumor immunity that can be increased by also engaging CD137.
Shilin Yang, Yi Yang, John Raycraft, Hongtao Zhang, Sandra Kanan

Proc Natl Acad Sci U S A· April 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis